[Fetal growth restriction as the disease of the placenta].

IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Orvosi hetilap Pub Date : 2025-03-02 DOI:10.1556/650.2025.33254
Balázs Gérecz, Zorán Belics, Gizella Molnár, Petronella Hupuczi
{"title":"[Fetal growth restriction as the disease of the placenta].","authors":"Balázs Gérecz, Zorán Belics, Gizella Molnár, Petronella Hupuczi","doi":"10.1556/650.2025.33254","DOIUrl":null,"url":null,"abstract":"<p><p>Fetal growth restriction (FGR) as a common pregnancy complication is generally defined as the failure of a fetus to achieve its genetically determined full growth potential due to placental dysfunction. Early-onset (<32. gestational week) FGR is associated strongly with abnormal trophoblastic invasion and consequent placental insufficiency. Conditions leading to FGR are the disorders inherent to the fetal-placental-maternal unit, fetal malnutrition, resulting in a significantly increased risk of stillbirth, neonatal morbidity, neonatal death, and long-term adverse outcome. Once the fetal size, typically using estimated fetal weight and/or abdominal circumference below the tenth percentile compared to gestational age reference standards, multimodality assessment (including Doppler velocimetry in umbilical, and middle cerebral arteries, CTG and biophysical profile) is recommended. At present, the most recognized criteria to define early and late FGR are those derived from an international Delphi survey consensus. Early diagnosis, close follow-up and timely delivery of pregnancies with FGR are of crucial importance for perinatal short- and long-term outcome. The main distinction between small for gestational age (SGA) and growth-restricted fetus is that the healthy SGA fetus may be small but not at increased risk of adverse perinatal outcome. Orv Hetil. 2025; 166(9): 331–340.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 9","pages":"331-340"},"PeriodicalIF":0.9000,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orvosi hetilap","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1556/650.2025.33254","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Fetal growth restriction (FGR) as a common pregnancy complication is generally defined as the failure of a fetus to achieve its genetically determined full growth potential due to placental dysfunction. Early-onset (<32. gestational week) FGR is associated strongly with abnormal trophoblastic invasion and consequent placental insufficiency. Conditions leading to FGR are the disorders inherent to the fetal-placental-maternal unit, fetal malnutrition, resulting in a significantly increased risk of stillbirth, neonatal morbidity, neonatal death, and long-term adverse outcome. Once the fetal size, typically using estimated fetal weight and/or abdominal circumference below the tenth percentile compared to gestational age reference standards, multimodality assessment (including Doppler velocimetry in umbilical, and middle cerebral arteries, CTG and biophysical profile) is recommended. At present, the most recognized criteria to define early and late FGR are those derived from an international Delphi survey consensus. Early diagnosis, close follow-up and timely delivery of pregnancies with FGR are of crucial importance for perinatal short- and long-term outcome. The main distinction between small for gestational age (SGA) and growth-restricted fetus is that the healthy SGA fetus may be small but not at increased risk of adverse perinatal outcome. Orv Hetil. 2025; 166(9): 331–340.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[胎儿生长受限作为胎盘疾病]。
胎儿生长受限(FGR)是一种常见的妊娠并发症,通常被定义为由于胎盘功能障碍导致胎儿未能实现其遗传决定的完全生长潜力。早发性(
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Orvosi hetilap
Orvosi hetilap MEDICINE, GENERAL & INTERNAL-
CiteScore
1.20
自引率
50.00%
发文量
274
期刊介绍: The journal publishes original and review papers in the fields of experimental and clinical medicine. It covers epidemiology, diagnostics, therapy and the prevention of human diseases as well as papers of medical history. Orvosi Hetilap is the oldest, still in-print, Hungarian publication and also the one-and-only weekly published scientific journal in Hungary. The strategy of the journal is based on the Curatorium of the Lajos Markusovszky Foundation and on the National and International Editorial Board. The 150 year-old journal is part of the Hungarian Cultural Heritage.
期刊最新文献
[Frequency of antibody formation during biological therapies in inflammatory bowel diseases]. [Coexistence of Ekbom syndrome and folie à deux]. [Therapeutic role of physical activity in relationship between chronic pain and sleep quality in musculoskeletal disorders]. [Merkel-cell carcinoma with gastric metastasis: rare tumor - rare metastasis]. [Relationship between early maladaptive schemas and quality of life in women with infertility].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1